MEDARTIS: Share price up over 20%!

The share price of the Basel-based medtech company MEDARTIS is rising sharply from a low level. Our top-up on October 10, 2024 at CHF 55.10 hit the bull's eye... and the rise in the share price could well continue. For one thing, MEDARTIS presented itself very optimistically at an investor conference at the end of last year and for another, the new CEO Matthias Schupp is increasingly arousing investors' imagination with his track record. At STRAUMANN, for example, he has developed a growth driver with the Neodent brand and increased its sales tenfold, with Neodent growing impressively quarter after quarter! An interview in Finanz und Wirtschaft a few days ago, in which his career, successes and outstanding qualities were highlighted, certainly contributed to the great share price performance. Another piece of news that also inspired confidence probably went largely unnoticed: the major shareholder Endeavour increased its stake in MEDARTIS by a high CHF 5 million. With Damien Tappy, it also has a representative on the Board of Directors. In addition, the planned growth ambitions in the USA are helping to boost market sentiment. If the upswing continues, we are setting a sell limit for 1/3 of the position at CHF 79, valid until the end of February! The medium-term price target is CHF 110!

MEDARTIS N is listed on the SIX Swiss Exchange under the symbol MED, the security number is 38,620,023, last price approx. CHF 67.